Kymriah (tisagenlecleucel) for the Treatment of Acute Lymphoblastic Leukaemia

Kymriah (tisagenlecleucel) is the first chimeric antigen receptor T cell (CAR-T) therapy approved in the US for the treatment of paediatric and young adult patients with B-cell precursor acute lymphoblastic leukaemia (ALL).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news